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Abstract
Primary ciliary dyskinesia (PCD) is a rare heterogenous condition that causes progressive suppurative lung disease,
chronic rhinosinusitis, chronic otitis media, infertility and abnormal situs. ‘Better Experimental Approaches to Treat
Primary Ciliary Dyskinesia’ (BEAT-PCD) is a network of scientists and clinicians coordinating research from basic science
through to clinical care with the intention of developing treatments and diagnostics that lead to improved long-term
outcomes for patients. BEAT-PCD activities are supported by EU funded COST Action (BM1407). The second BEAT-PCD
conference, and third PCD training school were held jointly in April 2017 in Valencia, Spain. Presentations and workshops
focussed on advancing the knowledge and skills relating to PCD in: basic science, epidemiology, diagnostic
testing, clinical management and clinical trials. The multidisciplinary conference provided an interactive platform for
exchanging ideas through a program of lectures, poster presentations, breakout sessions and workshops.
Three working groups met to plan consensus statements. Progress with BEAT-PCD projects was shared and
new collaborations were fostered. In this report, we summarize the meeting, highlighting developments made
during the meeting.
Introduction
Primary ciliary dyskinesia (PCD) is a rare syndrome
characterized by impaired mucociliary clearance due to
abnormal ciliary function. It is usually inherited as an
autosomal recessive condition, but X-linked inheritance
has been described; mutations in > 35 genes have been
reported to cause PCD, and more genes remain to be
found [1–3]. Clinical manifestations are caused by im-
paired mucociliary clearance and include recurrent lower
and upper respiratory tract symptoms which present
soon after birth [4, 5]. Pulmonary disease is progressive,
with recurrent infections leading to bronchiectasis and
impaired lung function. Sperm flagella have a similar
ultrastructure to cilia and male infertility is well
described but the prevalence is unclear due to lack of
data. Motile embryonic nodal cilia establish left-right
asymmetry and nearly half of PCD patients exhibit situs
inversus and 6–12% have heterotaxic syndromes (abnormal
arrangement of the left-right axis) which can be associated
with complex congenital cardiac defects [4]. To date there
are no specific treatments for PCD, and no evidence based
guidelines for clinical management of patients.
‘Better Experimental Approaches to Treat Primary
Ciliary Dyskinesia’ (BEAT-PCD; funded by COST Action
BM1407) is a network of scientists and clinicians coord-
inating research from basic science through to clinical
care with the intention of developing treatments and
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diagnostics to improve long-term outcomes for patients
(www.BEATPCD.org). Within the first 24 months we have
united a multidisciplinary network of 257 participants from
25 countries. Our collaborations have delivered major
advances in clinical care, in particular the first evidence-
based guidelines for the diagnosis of PCD, and the
commissioning of the European Reference Network (ERN)
PCD network, part of ERN-LUNG [6]. Step changes have
also been made through our research collaborations. For
example with BESTCILIA, an international PCD cohort
(iPCD) of over > 3000 patients providing infrastructure for
epidemiological studies [7] and a PCD registry to support
future clinical trials have been established [8], the first
multinational clinical trial of a treatment for PCD is analys-
ing results [9], and we have developed, validated and trans-
lated quality of life tools (QOL-PCD) for use as outcome
measures in trials [10–12].
Workshops at previous BEAT-PCD meetings [13] have
identified and prioritised research projects to provide
data to support H2020 grant applications. For example
BEAT-PCD scientists are conducting a preliminary study
to investigate the lung microbiome, and have undertaken
a review of pre-clinical models. BEAT-PCD clinicians
have identified urgent topics, and formed working group
to deliver guidelines for clinical management, e.g. analys-
ing and reporting ciliary ultrastructure, prevention of
cross-infection and defining respiratory exacerbations.
This manuscript summarises the 4-day BEAT-PCD
Conference meeting and Training school in Valencia
Spain in April 2017, including state-of-the-art lectures,
oral presentations, workshops and a poster session.
Work groups activities during the conference and
training school
BEAT-PCD activities are coordinated through four inte-
grated work groups: basic science, epidemiology, clinical
care and clinical trials (outcome measures). A major role
of the basic science work group (WG1) in BEAT-PCD is
to share information about advances in science that may
translate into clinical research and ultimately clinical
practice. PCD is a genetic disease making gene therapy
(GT) a potential therapeutic approach. The merits and
risks of two such approaches were discussed in plenary
talks by Heymut Omran (University of Munster,
Germany) and Francisco Dasi (Universitat de Valencia,
Valencia, Spain); in addition, a workshop about GT was
held during the meeting. Recent advances in imaging
technology are transforming biological research, but have
not all reached the clinic. Two such approaches (super-
resolution (SR) microscopy and electron tomography) in
cilia research were discussed by two plenary speakers,
Martin Knight (Queen Mary University of London, UK)
and Amelia Shoemark (Imperial College London, UK).
The role that these technologies may ultimately hold in
PCD diagnosis and therapy remains to be seen, but im-
portantly, the clinical community is now more fully aware
of the possibilities.
Important challenges in clinical management were dis-
cussed during the meeting, led by members of the
Epidemiology and Clinical Care Work Groups (WGs 2
& 3). The international PCD registry [8] and the inter-
national PCD cohort (iPCD cohort) [7] continue to
grow. The iPCD cohort now includes data form over
3200 patients; ongoing analyses look at lung function,
diagnostic evaluations, lobectomies and symptoms [14].
New partners can still join and share data from their pa-
tients, and already contributing data providers can add
data from new patients and add longitudinal data on old
patients. The role of a PCD group within the newly
developed ERN-LUNG was also presented. The ERNs
create a clear governance structure for knowledge sharing
and care coordination across EU, to improve access to
diagnosis and treatment, as well as the provision of high-
quality healthcare for patients with rare diseases [6].
A project within BEAT-PCD WGs 2 and 3 is exploring
the delivery of care for PCD across Europe through sur-
veys and interviews with clinicians. This project is rele-
vant because a previous survey, completed almost
10 years ago highlighted disparity across Europe [15].
Another crucial prerequisite for future clinical research
is the development of a proforma for standardised pro-
spective collection of clinical data such as symptoms
and signs; progress with this project was discussed
during the meeting.
Workshops and talks of relevance to clinical care took
place (WG3). An expert-led workshop focused on the
development of a consensus statement on cross-
infections in PCD. Another work shop concentrated on
airway clearance. Presentations on the management of
the ears and sinuses in patients were made, with a call
for clinical trials investigating the use of ventilation
tubes (VT).
Very few clinical trials in patients with PCD have been
conducted, with only one randomised controlled trial
(RCT) being published at the time of the conference
[16], and a few clinical trials ongoing. Therefore, WG4
focuses on developing the knowledge and networks for
future clinical trials. A challenge to clinical trials is the
rarity of the disease. In this regard, Claudia Kuehni
(University of Bern, CH) presented how physicians car-
ing for patients with PCD can learn from paediatric on-
cology, to ensure all patients have the opportunity to
participate in research [17]. In order to better under-
stand natural fluctuation of lung function in patients
with PCD, Bruna Rubbo (University of Southampton,
UK) presented the “Prospective observational multicentre
study on variability of lung function in stable PCD
patients” (PROVALF-PCD) study. Results from this study
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will enable a better definition of clinically relevant changes
in lung function when new therapies are studied in
patients with PCD. Finally, it is of importance for clarifica-
tion of the effects of different treatments in future
pharmaceutical RCTs to establish a functional definition
of a clinically significant deterioration or exacerbation in
PCD, whether it originates from or is located in the upper
or lower respiratory tract, or both. An expert working
group met to plan the methodology of a consensus
statement for defining pulmonary exacerbations.
State-of-the-art lectures
Six key note speakers presented on topics relevant to
BEAT-PCD. Two presentations concentrated on the po-
tential of gene therapy, and two considered new imaging
techniques to advance our knowledge of ciliary structure
and function. Further lectures reviewed the similarities
and differences between PCD and CF relating to radio-
logical findings and microbiology.
Gene therapy and PCD
Gene therapy is a term used to describe the technique of
repairing or replacing faulty genes in a patient’s cells.
However, genetic correction of mutated genes that cause
PCD in humans has not yet been successful. In ciliated
cell culture models and transgenic mouse models, 3
studies have been published where cilia with PCD muta-
tions were partially restored to normal ciliary beating
[18–20]. Lentiviral transfection of wild-type DNAI1 in-
duced normal ciliary movement in cultured human air-
way cells [18] and in vivo restored approximately 20% of
airway ciliary function of a mouse with a mutated
Dnaic1 gene [19]. Lai and colleagues used TALENs
(transcription activator-like effector endonucleases) to
correct mutations in DNAH11, resulting in 29% of the
cilia beating normally in cultured human cells [20].
Other gene editing techniques exist, for example
CRISPR-Cas9 that can be used in a similar way as
TALENs to correct mutations, and collectively, all of
these gene replacement or edit therapy techniques show
great promise for treating PCD [21]. Heymut Omran
spoke about the potential role of gene therapy to treat
PCD and discussed the safety concerns of such ap-
proaches, highlighting one early gene therapy trial using
transgenesis, that resulted in lethal side-effects [22]. He
went on to discuss delivering mRNA encoding the af-
fected gene product to the respiratory epithelium,
explaining how such an approach could not alter the
genome and thus prevent such complications. This ap-
proach would however, require regular delivery of the
therapy. He also showed research data on delivering
mRNA to multi-ciliated cell cultures to rescue PCD
phenotypes.
While the ability to correct defective genes causing
PCD have been partially demonstrated in-vitro, the big
challenges for the future is developing efficient,
immunologically safe, targeted delivery systems in
humans. With our increasing knowledge of the biology
of airway epithelial progenitor cells and their differenti-
ation pathways, one can see that targeting these imma-
ture epithelial progenitor cells using techniques such as
CRISPR-Cas9 to treat defective PCD genes may prove
an excellent target for future gene therapy studies.
Gene therapy: Lessons from alpha-1 antitrypsin deficiency
Alpha-1 antitrypsin deficiency (AATD) leads, in some
patients, to chronic obstructive pulmonary disease
(COPD) and liver disease. Francisco Dasi discussed on-
going gene therapy (GT) studies, and trials, that he and
colleagues have performed over 30 years to treat this
disorder, using transgene insertion into the genome.
He explained that GT is an experimental technique
aiming to correct the disease-specific genetic disorders.
There are different GT approaches, including the trans-
plantation of the gene to a patient with a deletion, gene
correction of the specific mutation, gene augmentation
to enhance the expression of gene of interest, or targeted
inhibition of gene expression. AATD is caused by muta-
tions in the Serpin Family A Member 1 (SERPINA1)
gene, which produces alpha-1 antitrypsin, an enzyme
that protects the lungs from the action of neutrophil
elastase. There is no cure for the disease. Augmentation
therapy is the only approved therapy that has shown
some clinical efficacy since it reduces the rate of lung
density decline preventing the progression of COPD to
more severe stages of the disease. There is no treatment
for the liver disease. Alternative strategies currently
under investigation include GT. AATD is a good candi-
date for GT approaches since it is a monogenic disease
and the mutations leading to the disease are well-
characterized.
He compared between viral vectors (retrovirus,
lentivirus, adenovirus, adeno-associated virus, herpes
simplex and some others), which take advantage of
the natural tropism and the viral capacity for infecting
cells; and non-viral vectors, which consist in naked DNA
and imply physical procedures (DNA complexes as
lipo- and poliplexes, nanoparticles and directed vectors).
Finally, he highlighted CRISPR-Cas9 as a revolution
in GT.
Based on his and others’ previous experience, Francisco
Dasi concluded that GT is a promising approach for a
number of diseases, including PCD, because it is a cure
for the disease and allows for personalised therapies.
However, more work is needed to make sure that it will be
safe and effective in patients.
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Super resolution microscopy
Two plenary talks addressed advances in imaging
technology. Classic light and fluorescence microscopy is
limited by the Rayleigh resolution limit of approximately
200 nm (half the wavelength of light) which corresponds
to the width of a cilium [23]. Martin Knight explained
how advances in super resolution (SR) microscopy cir-
cumvent this limitation, allowing resolution of fixed
samples down to ~ 20-40 nm. These methods can im-
prove the visualization of small molecular and cellular
structures, providing new understanding of the functioning
of cells and their components.
The major group of SR microscopy techniques are so
called stochastic switching methods, which use fluores-
cent molecules (proteins or dyes), which are switched
between fluorescence and dark states [24]. Complex stat-
istical analyses of the acquired set of images enables
emission of each fluorophore in the image to be very
precisely localized from which a SR image is
constructed. The resolution limit of these techniques
can be similar to transmission electron microscopy
(TEM) (~ 20 nm), but there are some technical limita-
tions (e.g. long acquisition time, limited fluorophore se-
lection and imaging depth, fixation of the samples is
required) [25, 26]. Examples of these techniques are
photoactivated localisation microscopy (PALM); stochas-
tic optical reconstruction microscopy (STORM) or
deconvoluted STORM (dSTORM).
Another SR microscopy technique is Structured
Illumination Microscopy (SIM). Using SIM, a grid pat-
tern is super-imposed over the specimen, generating an
interference pattern. A controlled, stepwise rotation of the
grid over the specimen generates a set of images. During
image processing, specialized algorithms define the shape
of the specimen to be deducted from the patterns. The
technique provides a resolution limit of approximately
100 nm, i.e. better than confocal which has a limit of
200 nm but not as good as PALM or STORM [25, 27].
However, in some cases, SIM can allow live cell imaging
and its simplicity and ease of use make it an exciting new
technique for pushing the limit of resolution. Finally,
Martin explained the use of light sheet microscopy that
can provide faster, high resolution imaging of living cells
or even whole organisms.
Although SR microscopy imaging of non-motile
primary cilia or fixed motile cilia has been successfully
achieved, the current SR techniques do not allow real-
time visualization of ciliary beating in live cells. The
resolution limit of SIM might not be enough to visualize
complex structures within the ciliary axoneme which
will require the use of more resolving SR techniques
such as PALM, STORM. Martin Knight concluded that,
these are exciting times for cilia imaging with the new
development of SR microscopy techniques helping to
resolve ciliary structures in live cells or with minimal
processing. Although not yet suitable for routine PCD
diagnostic use, SR microscopy supports fundamental
cilia research and has the potential to help resolve
difficult to diagnose cases.
Novel tools for PCD diagnostics and research: Electron
tomography
Amelia Shoemark spoke about electron tomography, a
technique that allows 3D imaging of cilia at high enough
resolution to demonstrate the holes left by proteins that
are absent from the cilium [28]. Transmission electron
microscopy (TEM) is central to PCD diagnosis and has
been used in research for decades (Fig. 1a). Advances to
the TEM technique will lead to better understanding of
the ciliary structure and ultimately improve diagnosis.
The ‘electron tomography’ technique, recently developed
(Fig. 1b) is an advanced TEM technique which improves
the resolution and spatial visualisation of structures
compared to traditional TEM. Rather than a single
image, as in TEM, in electron tomography, a series of
images of the sample are acquired at different angles.
Overlay of all the images generates a tomogram, based
on which, a computer 3D model can be generated
(Fig. 1c).
Amelia Shoemark started the session by describing the
tomography technique and the development of state of
the art ciliary electron tomography models by Nicastro
et al. [28]. The second half of the session focused on the
potential application of electron tomography in PCD
diagnostics and gene discovery. 15 to 30% of patients
with PCD have normal ciliary ultrastructure when
assessed by traditional TEM [2]. This leads to a delay in
diagnosis. In many patients who were previously thought
to have normal ciliary ultrastructure a structural defect
can be demonstrated by electron tomography [29, 30].
For instance, ultrastructural defects were demonstrated
in patients with variants in HYDIN, CCDC164, CCDC65
and DNAH11 genes where standard TEM is normal.
Electron tomography can also be useful in gene discov-
ery, even where a TEM defect is known, through identi-
fication of the subtle downstream structural effect of a
newly identified PCD gene [31]. The session closed with
a discussion around the advantages and disadvantages of
the tomography technique.
PCD is not a variant of CF: Chest imaging
In the plenary session ‘PCD is not a variant of Cystic
Fibrosis’ (CF), Philip Robinson (Royal Children’s
Hospital, Melbourne, Australia) summarised the differ-
ences between the two conditions with regards to
imaging, in particular chest high resolution computed
tomography (HRCT) (Fig. 2). He highlighted different
patterns of structural change in the two diseases. In
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PCD neonates with respiratory distress syndrome (RDS),
there is a high incidence of lobar collapse, commonly
limited to the upper lobes [32]. In infants with CF up to
80% can have an abnormal CT, but RDS and lobar
changes are rarely seen; bronchial wall thickening and
gas trapping are the commonest findings [33] and
there is no predominance for the upper lobes. The
pattern of disease seen in infants with PCD is there-
fore different than in CF and has implications for fu-
ture lung health. Potential future studies include the
long term assessment of PCD patients with neonatal
upper lobe disease.
The findings from early childhood contrast to those in
older patients where middle and lower lobe disease is
more prevalent in PCD, and upper lobe disease more
common in CF [34]. Dextrocardia, extensive tree-in-bud
patterns, septal thickening and whole lobar collapse are
findings seen in patients with PCD. Commonly used
HRCT scoring systems [35, 36] have been developed
from structural changes characteristic of CF lung dis-
ease. As findings in PCD are so different, unique aspects
of structural disease could be missed if a CF derived
score is directly applied and could limit the description
of longitudinal changes and effects of interventions. A
collaborative group is developing HRCT scores specifically
for PCD, including quantitative outcomes.
PCD is not a variant of CF: Microbiology
Helle Krogh Johansen (University of Copenhagen,
Denmark) delivered a state-of-the-art presentation dis-
cussing the similarities and differences in the airway
microbiology of PCD and CF. The topic is important be-
cause PCD treatment is often directed by CF guidelines.
She described the predominance of Haemophilus
influenzae as a pathogen from the airways of PCD
patients, infecting 40–80% of PCD patients annually.
Streptococcus pneumoniae, Moraxella catarrhalis,
Staphylococcus aureus, and Burkholderia spp. are less
prevalent but are not rare, and although Pseudomonas
aeruginosa appears to be less common in children
with PCD (approximately 10% in comparison to 30%
of CF) it is a common pathogen in adults with PCD.
P aeruginosa colonises the airway in both conditions,
persistence of the same clone has been described for
prolonged periods and bacterial adaptation pathways
a b
c d
Fig. 1 a A Transmission electron microscopy image of a cilium in cross section. b Electron tomography image of a cilium in cross section with key
features coloured (Yellow - microtubular doublet, blue - outer dynein arm, pink - inner dynein arm, green - dynein regulatory complex, orange – central
complex). c Electron tomogram image of a normal microtubular doublet with improved resolution following computer averaging when compared to the
microtubular doublet in image A circled in red. d Averaged microtubular doublet tomogram from a subject with PCD due to an inner and outer dynein
arm defect
Fig. 2 CT images showing dextrocardia and middle lobe abnormalities
in adolescent patients with PCD (above), contrasting to upper lobe
disease in CF (below)
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are similar in PCD and CF [37]. PCD microbiology is
therefore in many aspects comparable to CF, and in
the absence of disease-specific evidence, the speaker
argued that it is reasonable to manage infections using CF
guidelines, although drug doses may be different.
Oral presentations
A number of short presentations were made throughout
the conference, addressing topics of importance for
BEAT-PCD, from basic science and clinical perspectives.
Basic science oral presentations
Markers of oxidative stress have been detected in
exhaled breath condensate of children with PCD [38]
and Ana Reula presented her ongoing PhD research in-
vestigating oxidative stress in PCD airway epithelium.
She analysed reactive oxygen and nitrogen species, gluta-
thione (GSH), and markers of oxidative lipid and protein
damage, apoptosis and mitochondria function by flow
cytometry in nasal epithelial cells from healthy, PCD
and disease control subjects. There was no significant
difference in apoptosis, carbonylated proteins, ratio oxi-
dized/reduced lipids, mitochondrial mass and nitric
oxide between groups. PCD patients’ airway cells had
raised GSH, hydrogen peroxide and total superoxide O2
−
and reduced mitochondrial O2
−. Ana Reula concluded
that oxidative stress was implicated in the pathophysi-
ology of PCD and may be dependent on O2
− and H2O2
production.
Mahmood Fassad (University College London, UK)
spoke about a multigene targeted next generation se-
quencing approach for novel gene discovery and diagno-
sis in PCD. A total of 185 PCD patients were studied
and a number of novel candidate genes were identified.
These now need to be characterised in expression studies
using the model multi-ciliated organism Paramecium. He
went on to emphasise the usefulness of routine genetic
testing for PCD diagnosis.
Osman Sezerman has been working closely with Turkish
and Japanese populations of patients with aortic aneu-
risms and performing genome wide association studies to
identify single nucleotide polymorphisms within genes.
Data was then analysed systematically to look at the bio-
chemical pathways that may be affected by the mutated
genes. The data shows that predictable pathways, such as
MAP-kinase, were involved. It is thought that this may aid
clinical management and diagnosis. Osman Sezerman’s
aim is to incorporate multiple clinical phenotypes with
genetics for a personalised medicine approach. He sug-
gested that this approach would work well in PCD.
However, the complexity caused by consanguinity, and
multiple disease causing genes in patients with PCD may
complicate the picture.
The intraflagella transport (IFT) IFT46 gene is thought
to be associated with regulation and maintenance of cil-
iary length during ciliogenesis [39]. Lara Millán pre-
sented a study measuring ciliary length in 27 PCD
patients’ samples in relation to high-speed video micros-
copy (HSVM) and TEM data, and IFT46, FOXJ1 and
DNAI2 gene expression. Cilia length was measured in
semi-thin TEM sections of airway epithelial samples. 9/
27 (33%) patients had normal ciliary length (> 5.9 μm)
including 6 patients with normal ultrastructure and
function, and 3 with dynein arm defects and immotile
cilia. 12/27 (44%) patients had shortened ciliary length
(< 5.9 μm) including 3 patients with normal ultrastruc-
ture and 9 with dynein arm defects, however all had an
abnormal beating pattern. 3/27 (11%) patients had ciliary
aplasia and 3 (11%) patients had cilia that could not be
measured. Real-time (RT)-PCR showed a 1–2 fold re-
duction in FOXJ1 and DNAI1 gene expression in PCD
cases relative to non-PCD controls that were particularly
associated with samples that had short cilia or ciliary
aplasia. IFT46 expression was reduced in “the short cilia
group” but this was not associated with PCD. During
questioning, the participants suggested that reduced
ciliary length could be due to secondary infection and
on-going ciliogenesis therefore further experiments
would need to take these potential confounding factors
into account.
Male infertility is associated with approximately half of
the currently reported PCD genes, yet the effect of these
mutations on sperm tail physiology is not understood.
Absence of KIF3A in a Kif3a−/− knockout mouse caused
disruption of the manchette organization and abnormal
shaping of the sperm head [40] and prevented normal
intramanchette of meiosis-specific nuclear structural
protein 1, which is required for outer dynein arm assem-
bly within the axonemes of both sperm tail and motile
cilia. Loss of Spef2 gene function in mouse caused a
PCD model phenotype [41]. Anu Sironen demonstrated
that SPEF2 co-localised with IFT20 and that intra-
manchette transport of IFT20 was delayed in the ab-
sence of functional SPEF2. In conclusion, IFT was
required for both sperm tail formation and manchette
function and the functional role of different protein iso-
forms in motile cilia and sperm tail is yet to be fully
understood. Anu Sironen proposed SPEF2 as a poten-
tially new PCD candidate gene and speculated that
SPEF2 protein may act as an adaptor for cargo
molecules during dynein 1 mediated transport.
Clinical oral presentations
Antonio Moreno reviewed the literature relating to the
definition of pulmonary exacerbations in CF, which may
help inform the development of a consensus definition
for PCD patients. In clinical practice the physician
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makes the diagnosis based on changes in signs, symp-
toms, spirometry, chest radiographs and/ or culture of
microbiological samples. However, a more standardised
definition is needed where exacerbations are used as an
outcome measure for clinical trials. With no consensus
definition, recent PCD trials have taken different ap-
proaches to defining exacerbations [9, 16], and even in
CF there remains no consensus for a single standardised
definition [42]. Physician-decision to treat is influenced
by many factors and is therefore unreliable as an out-
come measure for RCTs; symptom-defined decisions to
treat (e.g. Fuchs [43] or modified-Fuchs [42]) is probably
better for clinical trials but has not been formally vali-
dated; and there is no evidence that scoring systems are
reliable or valid [44, 45]. Participants discussed the par-
ticular difficulties in defining an exacerbation in PCD,
since patients have significant symptoms even when
well, and their wet cough does not clear with antibiotics.
Teresa Romero reported a study comparing the
broncho-responsiveness to direct and indirect agonists,
methacholine, and AMP. Patients with PCD had a
higher prevalence of airway hyper-responsiveness (31%)
than healthy volunteers (9%) (p = 0.06).
Emily Frost reported a study investigating the use of
immunofluorescence (IF) labelling of ciliary proteins as a
diagnostic test for PCD. The study, which has recently
been published, used immunofluorescent labelling of
nasal brushings from a discovery cohort of 35 patients
diagnosed with PCD by ciliary ultrastructure, and a diag-
nostic accuracy cohort of 386 patients referred with
symptoms suggestive of disease [46]. In the validation
cohort IF successfully identified 22 of 25 patients with
PCD and staining was normal in all 252 in whom PCD
was considered highly unlikely. This indicates that the
method is highly specific, but has limited sensitivity and
therefore it cannot be used as a stand-alone test.
Heymut Omran updated the conference about ERN-
LUNG [6]. The EU is building networks of reference
centres to provide quality, expertise, specialism, research
and clinical care across Europe. PCD is a core network
within the ERN-LUNG. To ensure adequate expertise
and experience, PCD reference centres will be expected
to care for at least 30 patients, investigate > 70 patients a
year using nasal nitric oxide, EM and HSVM and to
contribute a minimum dataset to a European PCD regis-
try annually. Nine European centres currently have sta-
tus as full members of this PCD core network. It is
expected that these members will contribute to collect-
ively improving the standard of PCD care across Europe.
Mikkel Alanin discussed chronic rhinosinusitis (CRS)
and bacterial sinusitis which affect most patients with
PCD, adversely affecting quality of life (QoL). Medical
therapies for CRS include nasal irrigation with saline,
topical nasal steroids and antibiotics. However, none of
these treatments have been formally evaluated in PCD.
Endoscopic sinus surgery (ESS) is a well-established CRS
treatment in general. Several small, non-randomised
studies have evaluated the effect of ESS in PCD and they
consistently show benefit [47–49]. Further, ESS can
eradicate sinus bacteria and may protect the lower air-
ways from repeated bacterial colonization from the si-
nuses [47, 50]. Testing the efficacy of CRS treatments in
PCD in RCTs is now needed to allow us to develop evi-
dence based guidelines. Otitis media with effusion
(OME) affects almost all PCD children causing conduct-
ive hearing loss that can impair speech development and
QoL. OME may spontaneously improve by age 12 but con-
tinues into adulthood in many patients [51]. Ventilation
tubes (VT) can restore hearing in patients with OME.
However, in PCD use of VT is controversial since VT in-
sertion leads to prolonged otorrhoea in 33–100% of pa-
tients [51–53] compared to less than 5% of the general
paediatric population. A comparative study on VT indica-
tions and efficiency in PCD is highly warranted and an
international collaboration between ENT specialists was
established during the conference.
Ongoing and new projects
The Conference highlighted some of the collaborative
BEATPCD projects (Fig. 3). Projects are currently in dif-
ferent stages of development, with some more advanced
(e.g. publication of iPCD data) while others still in devel-
opment (e.g. protocol development). More details on the
projects and their current status are included in
Additional file 1.
In addition to the updates about ongoing projects,
Claudia Kuehni gave a talk on “Clinical studies in PCD:
can we learn from Paediatric Oncology” discussing how
we can use experiences from paediatric oncology to im-
prove recruitment to PCD projects [17]. The following
actions were crucial in the success of improving
treatment in paediatric oncology:
 Centralized care: patients are only treated in a few
specialised clinics, which collaborate together in a
network, and there are strict standards for all
centres;
 Central registration: all patients are registered in
clinical or population-based national registries and
data is pooled internationally for research;
 Standardised care: care for patients is standardised
on national and international level;
 Clinical studies: almost all patients are invited to
participate in one or more clinical trials.
Claudia Kuehni compared the situation in PCD with
paediatric oncology 30–40 years ago, with many
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malignancies occurring at very low prevalence and vary-
ing practices of follow-up and treatment of childhood
cancer. Internationally recognized study protocols then
changed the picture. All children diagnosed with child-
hood cancer were ultimately treated according to the re-
spective protocols. This led to a dramatic increase in
survival over the last 40 years, better understanding of
the disease and of different treatment options as well as
near 100% participation of these patients in clinical tri-
als. In contrast to childhood cancer, for which mortality
is a well-defined outcome marker, different possible
outcome parameters for studies in patients with PCD
need validating – lung function being one of the most
important ones.
Training school workshops
A variety of workshops were designed to address the
training needs of a multidisciplinary network at differing
stages of career.
Airway clearance workshop
Gemma Marsh and Victoria Keenan facilitated a work-
shop on airway clearance. The aims of this workshop
were:
 To introduce the concepts of upper and lower
airway clearance in PCD
 To share and discuss the UK National PCD Service
Physiotherapy guidelines (unpublished)
 To bring together physiotherapists from different
countries, with the aim of sharing practice and
developing a network to guide/design future
research projects.
The workshop was divided into two sections, an oral
presentation and a practical workshop. The facilitators
introduced concepts of both upper and lower airway
clearance techniques currently utilised in the UK. The
oral presentation was designed to be interactive and cre-
ate discussion using multimedia (videos, pictures); it re-
lated research evidence and clinical experience to
underpin practice. This was followed by an interactive
practical session. Attendees had opportunity to practice
a number of techniques and equipment, and to discuss
the pros, cons and practicalities of each.
Developing a network of PCD physiotherapists is
essential in order to share practice and develop research
opportunities. Currently this network is lacking and
given the nature of rare diseases, this can mean thera-
pists are working in non-specialist areas or in isolation.
In the spirit of BEAT-PCD this strengthening of infra-
structure and building links for therapists for clinical
support, experience and knowledge unites the aim to
improve patient experience and outcomes.
Transition workshop
A workshop on transition between paediatric and adult
services was hosted by Amanda Harris and Amanda
Friend. An effective transition between paediatric and
adult services improves the long term outcomes of
young people with chronic health needs, improving
Fig. 3 Schematic of ongoing and new projects led by BEAT-PCD members, highlighting their relationship to each of the four work groups (WG)
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morbidity and mortality [54–56]. In practice there is
often confusion between ‘transition’ and ‘transfer’ with
the education and empowerment of young people being
overlooked. This interactive workshop aimed to:
 Explore the differences between transition and
transfer
 Discuss how practices differ across Europe,
focussing on common challenges and good practice
 Introduce the “Ready, Steady, Go” (RSG) programme
as a tool to aid transition
 Discuss how to improve outcomes for children and
young people with PCD going into adult services
Morbidity and mortality has been shown to increase
following transfer from paediatric to adult services for
many different diseases [57–61]. A planned and pur-
poseful transition programme, individualised around the
young person can improve the experience and outcomes
of the young people [54–56]. Transition is a process of
education and empowerment slowly moving the em-
phasis from the parent to their child ensuring that on
transfer, the young adult is equipped with the skills and
knowledge they need to manage their condition. It seeks
to prepare the young person for adult services rather
than preparing the adult service to receive the young
person [62]. Transfer is a single event when care is
passed from paediatric to the adult services.
The RSG programme is a simple but comprehensive
tool to help guide transition. It is a holistic programme
encompassing all aspects of daily life allowing the young
person to guide their clinic appointments to focus on
the issues that matter to them. RSG ensures that the
medical, psychosocial, and vocational needs of the young
person are addressed following a structured adaptable
transition programme [62]. Starting the process early,
around the time of transfer to senior/high school, allows
plenty of time to deliver the programme in bite size
chunks.
This interactive workshop allowed much discussion
around the differences in health care provision and cul-
tures across the different countries and its impact on the
transition process for young people. Many common
challenges and successes were expressed. Transition ar-
rangements differed across Europe but overall the RSG
programme was seen as a good tool that would serve to
guide transition in most situations.
Gene therapy workshop
Francisco Dasi and Daniel Pellicer hosted a workshop
on gene therapy (GT). The term “Gene Therapy” was
coined many years ago by researchers speculating on the
possibility of correcting specific genetic defects by
introducing external genetic material to correct the de-
fective gene and potentially getting a cure for inherited
monogenic diseases. From the beginning, it became clear
that the main challenge to GT, before it could be used
into the clinical practice, was the construction of safe
and efficient vectors that allowed the delivery of the
therapeutic genetic material. Three decades later, some
of these problems remain unsolved, however, in recent
years there have been advances that indicate promising
results for the use of GT in daily clinical practice.
Significant advances have been made in the genetic as-
pects of PCD, which has led to the identification of sev-
eral genes that could be candidates for the different GT
techniques. Since there is currently no treatment for
PCD, GT could be a therapeutic alternative (similar to
that already existing in other rare respiratory diseases)
that would potentially lead to a cure.
The facilitators’ used their experience from AATD
gene therapy, to provide awareness of the basic concepts
of GT which might be translated into PCD research.
Daniel Pellicer gave the initial talk, where the following
items were introduced and discussed:
 Basic concepts of replacement GT and gene editing;
 The progress made since the initial steps of GT and
the problems encountered and still unresolved;
 The different strategies used for gene transfer (in
vivo vs. ex vivo and viral vs. non-viral).
Following this theoretical discussion, there was a prac-
tical part in which participants were asked to split into
two groups with the purpose that each group developed
its own GT project in PCD. Participants developed a
10 min presentation in which they explained their re-
search projects. Both groups chose to use systems of
gene editing and non-viral gene therapy. Finally, in a
final 15 min discussion, both projects were discussed
and special emphasis was placed on the challenges
(choosing the appropriate candidate gene; delivery prob-
lems; how to overcome undesired immune responses
and how to avoid off-target effects), the ethical aspects
and the commercial viability of GT in PCD.
The final conclusion was that, despite several hur-
dles that need to be overcome, GT is potentially a
curative treatment that could be used for the treat-
ment of PCD. In addition, the technology could
generate patents and would therefore be of interest to
the pharmaceutical companies. Since some of the
members of the BEAT-PCD group have previous
experience in GT and others in the development of
experimental models of the disease, we proposed the
possibility of using these models to evaluate the
efficiency of the GT techniques in the treatment of
the disease.
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High-speed video microscopy analysis workshop
BEAT-PCD delegates attended a workshop on HSVM
analysis hosted by Claire Jackson, Robert Hirst and Ana
Reula. The workshop focussed on the role and methods
of HSVM within the diagnostic pathway in the context
of the recently published European Respiratory Society
Diagnostic Guidelines [2, 63]. The work group discussed
the need for expertise, a standardised approach, specia-
lised equipment [64]. It was recommended that centres
should develop their own normative data since ex vivo
ciliary function varies depending on environmental con-
ditions, yet standardised methods are not in place; for
example some centres measure ciliary function at 37 °C,
whilst other conduct analyses at room temperature,
factors such as pH and culture medium might also
influence results.
The facilitators emphasised the importance of taking
samples when patients have been free of an upper re-
spiratory infection for at least 4 weeks to minimise the
likelihood of secondary defects. Ciliary beat frequency
(CBF) is a quantitative measure of ciliary function which
can be calculated by manual [65] or computational ana-
lysis [66, 67], however CBF without ciliary beat pattern
(CBP) analysis misses cases of PCD when CBF is within
‘normal range’. The group discussed the subjective
nature of CBP analysis and the potential for objective
parameters to be measured [67].
Workshop participants reviewed examples of normal
ciliary movement with mucociliary clearance, and then
examples of cilia that were immotile, rotating, stiff, stag-
gered and unsynchronised. It was emphasised that more
subtle abnormalities of ciliary movement could easily be
missed by HSVM [68]. In conclusion, HSVM was shown
to be a valuable diagnostic method when conducted and
interpreted correctly.
Consensus statement workshops
The Inaugural BEAT-PCD Conference in 2015 had iden-
tified topics for consensus statements [13]. Three of
these topics were taken forward during Workshops of
experts during this Conference. A consensus statement
to define pulmonary exacerbations was considered im-
portant for future clinical trials; consensus guidelines for
the prevention of cross-infections between patients was
also considered a priority; and the European Respiratory
Society Guidelines for diagnosing PCD had called for
standardisation of testing and reporting of TEM [2].
Twenty pulmonologists and a nurse specialist formed
the Working Group to define pulmonary exacerbations;
Siobhan Carr and Jane Lucas invited a pulmonologist
from each COST country represented at the conference.
A short presentation reviewed definitions used in CF
and non-CF bronchiectasis. The Workshop members
decided that a definition of pulmonary exacerbation was
needed for research purposes rather than for clinical
care, to enable standardised use across clinical trials. It
was agreed that a modified Delphi e-survey would be
used to reach consensus; we also decided to invite more
adult pulmonologists, some physiotherapists and patient
representatives to join the working group.
Kim Nielsen and Helle Krogh Johansen convened a
multidisciplinary, multinational working group to de-
velop a consensus statement for PCD and cross-
infections. There were considerable differences within
the group concerning present practices in out-patients,
in-patients and for patients attending meetings. It was
agreed that there are similarities between CF and PCD
microbiology, and in the absence of evidence to the con-
trary cross-infection between patients is a significant
risk. The group decided to develop a consensus guide-
line for publication, working electronically until meeting
at next year’s conference.
Amelia Shoemark and Estelle Escudier invited 12 PCD
electron microscopy experts representing 9 countries to
meet in person and via video link to plan a consensus
statement for reporting ciliary ultrastructure by TEM.
European diagnostic guidelines recommend ‘a hallmark
defect’ at TEM as a confirmatory diagnostic test for
PCD [2]. However, there is currently no international
classification of ultrastructure for cilia biopsies and there
is considerable heterogeneity among pathology reports
describing PCD. Differences in reporting can result in
difference in interpretation of findings between centres.
In recent years advances in genetic testing and molecu-
lar biology have redefined many aspects of the disease
further complicating the use of traditional reporting ter-
minology. For example the use of the term radial spoke
defect has been used to describe both central complex
defects and microtubular disarrangement defects [69–
71]. In renal allograft pathology, internationally agreed
pathology classification known as ‘the Banff criteria’ [72]
has been shown to improve disease outcome. The aim of
this workshop was to form a working group to provide
an internationally agreed ultrastructural classification for
PCD diagnosis [72].
Three objectives for the classification statement were
formulated and agreed at the meeting:
 To define hallmark defects diagnostic for PCD
 To describe features which should be included in a
TEM report to assist multidisciplinary diagnosis of
PCD or exclusion of the condition
 To define adequacy of a diagnostic sample
During the TEM workshop, experts created a list of
features which could be included in a pathology report.
The inclusion of these items will be considered by Delphi
consensus survey by 16 members, representing 16
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institutions worldwide, to form the guideline. The first
draft of the consensus guideline will be completed by
September 2017. The guideline will then be tested and
updated by the group prior to meeting at the next
BEAT-PCD conference.
Short term scientific missions
STSMs provide an excellent training resource with the
opportunity to visit a research institution in another
country, allowing access to resources and expertise not
available in the participants’ institution. The aim is that
early stage researchers (ESRs) will use the knowledge
and skills acquired during the STSM to advance PCD re-
search at their institution and develop collaborative pro-
jects supporting the aims of BEAT-PCD. STSMs can
also be used to invite an expert to a developing PCD
centre to provide on-site training and expertise. Up to
15 bursaries are awarded each year. More information
on STSM applications can be found on the BEAT-PCD
website (http://www.BEAT-PCD.org/).
During this Conference and Training School, STSM
participants presented overviews of their experience
during their visit.
Ana Reula, University of Valencia, spent 3 months at
the University of Southampton UK, hosted by Jane
Lucas’ group. She gained experience in the preparation
and analysis of diagnostic test samples for HSVM, TEM
and IF. In particular, she learnt to perform culture of re-
spiratory epithelium at air-liquid interface (ALI), and
sample preparation and analysis of ciliated ALI-cultures.
She attended multidisciplinary diagnostic meetings, PCD
research meetings and had the opportunity to visit the
Royal Brompton Hospital, London, to observe the
diagnostic pathway at another UK centre.
Myrofora Goutaki, University of Bern CH, visited the
ENT clinic of the Kremlin-Bicetre Hospital, Paris France,
supervised by Jean-François Papon. She observed the
diagnostic, follow-up and management protocols of PCD
patients, observed interviews, clinical examinations and
nasal functional measurements and got an overview of
the local PCD databases. She identified important ques-
tions of clinical relevance for the ENT management and
follow-up of PCD patients and discussed ongoing pro-
jects and development of future collaborative project
with members of the French multidisciplinary PCD
team.
Raquel Jacinto from the Nova Medical School (Lisbon,
Portugal) visited the lab of Mauro Pistello at the University
of Pisa, Italy. She learned cell transfection skills, which she
has applied to building new zebrafish PCD mutants in her
laboratory for a collaborative project testing CRSPR-Cas9
gene editing for mutating PCD genes in parallel systems:
the zebrafish and ex vivo human respiratory nasal
epithelia.
Mieke Boon and Martine Jaspers, Leuven Belgium, vis-
ited Heymut Omran’s lab in Munster Germany, to learn
the technical challenges of ALI culture and IF antibody
staining. Research collaboration was enhanced with the
exchange of genetic analysis techniques and implemen-
tation of the patient registry for research and clinical
applications.
Poster session
A key objective of BEAT-PCD is to promote involvement
of ESRs in research and all the activities of BEAT-PCD.
The poster session of the Conference and Training School
demonstrated the success of PCD research by ESRs
(Table 1: list of posters; Part 2: poster abstracts). The post-
ers came from a broad range of disciplines: epidemiologic
studies, clinical research and basic science projects,
reflecting the multidisciplinary nature of the BEAT-PCD
network. Topics ranged from a study of the QoL of pa-
tients with PCD, to the assessment of novel methods for
the diagnosis of the disease. The session included also a
wide range of important basic science projects from
microbiology to genetic studies. The poster session
attracted senior clinicians, scientists and young
researchers allowing an excellent opportunity for cross
pollination of ideas and potential future collaborations.
Difficult case discussions: Diagnostic testing
This interactive session on diagnostic dilemmas was new
to the BEAT-PCD programme and proved very popular
and informative. Chaired by Claire Hogg and Kim
Nielsen, participants were encouraged to bring their
diagnostic dilemmas in the form of clinical history, in-
cluding screening tests and other investigative pathway
details. Ciliary function (HSVM clips) and ultrastructure
(TEM) and any other advanced diagnostic tests such as
IF, genetics or 3D electron tomography were then
viewed to allow for the assembled field of experts to
share their opinions and own similar experiences.
Cases presented included:
 Deborah Snijders (Italy) presented a case where
TEM had been done multiple times and showed a
central complex defect - All agreed this was PCD.
She highlighted that in their diagnostic guidelines
TEM for central complex defects is not considered
‘hallmark’ in these cases making it difficult to
officially confirm.
 Andreia Pinto (Portugal) showed a TEM only case.
She did not have the clinical details for this case but
presented multiple TEM views for the panel. Estelle
Escudier and Amelia Shoemark agreed that there
was an absence of outer dynein arms. This
conclusion was confirmed by other experts in the
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room highlighting the importance of holding such a
multidisciplinary meeting.
 Claire Hogg (UK), showed 2 cases:
 A series of unusual TEM findings showing
interconnections between the ciliary axonemal
cross sections. The axonemal ultrastructure was
otherwise normal. These cases had a high
prevalence of asthma/atopy phenotypes, but also
had low or borderline low nasal NO. No-one else
had seen these unusual appearances, but a fruitful
discussion about possible aetiology and possible
staining methods to determine their structure
was held.
 A case of very subtle ODA defects at the tip of the
cilia with some sections apparently having normal
ultrastructure. This partial defect was subsequently
found to be caused by a DNAH5 mutation.
Experience was shared about these more subtle
defects and the role of extended testing in all
difficult cases to help solve them was debated.
 Carmen Casaulta (Switzerland) presented a clinical
case with typical phenotype but normal TEM. Her
centre did not have access to HSVM, and so the
discussion centred on the valuable role of additional
testing, HSVM in particular, where typical cases
have normal TEM. DNAH11 mutations was
discussed as a likely mutation and it was suggested
that in addition to investigating the cilia beat pattern
IF, genetics and electron tomography could be
considered.
Table 1 Details of 16 posters from 9 countries, presented at the 2nd BEAT-PCD Conference & 3rd PCD Training School (only listed if
authors agreed to have the title published)
Poster title Authors (Country of first author)
Development of a bioinformatics analysis method for diagnosis of
Primary Ciliary Dyskinesia
Alik E (Turkey)
Quality of life in patients with primary ciliary dyskinesia: a systematic
review
Behan L, Rubbo B, Lucas JS, Dunn Galvin A (Ireland & UK)
Estimation of cell number in a three-dimensional cell cluster –
comparison of different 3D nuclei calculating methods.
Kraft M, Bukowy-Bieryllo Z, Fedoruk-Wyszomirska A, Dabrowski M, Wyszko E,
Pikulska M, Witt M, Zietkiewicz E (Poland)
Diagnosing Primary Ciliary Dyskinesia (PCD) using electron microscopy
and exome sequencing
Crowley S, Shoemark A, Kulseth MA, Reinholt F, Heimdal K (Norway)
In vitro differentiation of respiratory epithelial cells in the sequential
culture model
Dabrowski M, Bukowy-Bieryllo Z, Wyszomirska-Fedoruk A, Pikulska M, Witt M,
Zietkiewicz E (Poland)
Preliminary Results of Whole Exome Sequencing in Turkish Primary
Ciliary Dyskinesia Patients- Hacettepe University Experience: “Three
candidate genes, five novel and two known mutations”
Emiralioğlu N, Taşkıran E, Koşukçu C, Tuğcu GD, Eşref S, Hızal MG, Yalçın E,
Ersöz DD, Kiper N, Alikaşifoğlu M, Özçelik U (Turkey)
Antibiotic resistance of Haemophilus influenza in Primary Ciliary
Dyskinesia Patients
Çıkı K, Demirci S, Sancak B, Emiralioğlu N, Tuğcu GD, Eşref S, Hızal MG, Yalçın
EG, Ersöz DD, Kiper N, Şener B, Özçelik U (Turkey)
Changes in height and BMI in children and adolescents with Primary
Ciliary Dyskinesia: an iPCD Cohort study
Goutaki M, Halbeisen F, Maurer E, Casaulta C, Crowley S, Haarman E, Lucas JS,
Morgan L, Nielsen KG, Santamaria F, Schwerk N, Thouvenin G, Yiallouros P,
Latzin P, Kuehni CE (Switzerland)
Lung growth in children and young adults with Primary Ciliary
Dyskinesia: an iPCD Cohort study
Halbeisen FS, Goutaki M, Maurer E, Casaulta C, Crowley S, Haarman E, Lucas
JS, Morgan L, Nielsen KG, Santamaria F, Schwerk N, Thouvenin G, Yiallouros P,
Zivkovic Z, Latzin P, Kuehni CE (Switzerland)
The effect of L-Arginine on Cilia Beat Frequency in PCD patients,
non-PCD referrals and healthy controls
Kouis P, Hadjisavvas A, Middleton N,Papatheodorou S, Kyriacou K, Yiallouros
PK (Cyprus)
The role of Rabconnectin3a in cilia length regulation Tavares B, Pestana S, Lopes S (Portugal)
Late diagnosis of the PCD is still a great risk Martinu V, Dvorakova P, Uhlik J, Pohunek P (Czech Republic)
Quality of life questionnaire for Spanish patients with Primary Ciliary
Dyskinesia
Reula A, Behan L, Pastor S, Castillo S, Bañuls S, Navarro-García MM, Lucas JS,
Dasi F, Escribano A, Armengot M (Spain)
Ten years’ experience of Primary Ciliary Dyskinesia Diagnostic Testing Rubbo B, Behan L, Lima de Queiroz AP, Goggin P, Jackson C, Packham S,
Walker W, Lucas JS (UK)
A high prevalence CCDC103 p.His154Pro mutation causing primary
ciliary dyskinesia is associated with normal diagnostic investigations
Shoemark A, Moya E, Hirst RA, Patel MP, Robson EA, Hayward J, Scully J,
Fassad MR, Lamb W, Schmidts M, Dixon M, Patel-King RS, Rogers AV, Rutman
A, Jackson CL, Goggin P, Ollosson S, Carr S, Walker W, Adler B, Loebinger MR,
Wilson R, Bush A, Williams H, Boustred C, Jenkins L, Sheridan E, Chung EMK,
Watson CM, Cullup T, Lucas JS, Kenia P, O’Callaghan C, King SM, Hogg C,
Mitchison HM (UK)
Use of electron tomography to confirm the diagnosis of primary
ciliary dyskinesia
Shoemark A, Burgoyne T, Kwan R, Cahill T, Scully J, Dixon M, Patel M, Bush A,
Mitchison H*, Hogg C* (UK)
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The session ended with a discussion about developing
networks for discussion of difficult diagnostic dilemmas.
This is something that exists in an informal setting
where larger and more developed centres review cases
from time to time, with the added provision of training.
However, further discussion about developing a formal
network is warranted.
Difficult case discussions: Clinical management
The management of PCD patients remains challenging,
in the main, because there is a limited evidence base to
guide clinicians on best practice. To date there have only
been two RCTs in PCD.
One tested hypertonic saline and did not demonstrate a
significant difference in the primary outcome measure be-
tween treatment and placebo groups (St Georges
Respiratory Questionnaire) [16], but did report differences
in one of the sub-domains of the secondary outcome meas-
ure (Quality of Life Bronchiectasis questionnaire QOL-B)..
The other assesses the effect of azithromycin, and results
are not yet available [9]. Hence management is based on
expert opinion, consensus guidelines, and extrapolated
from the larger evidence base available for patients with
CF. Though it has many similarities to PCD, CF clearly has
a different pathophysiology and applying the same treat-
ment strategies from CF to PCD may not only be ineffect-
ive but potentially detrimental [73]. Discussion of difficult
clinical cases of PCD is therefore key to further developing
expert consensus on management. Four such challenging
cases were presented during this interactive session.
Cases presented included:
 Suzanne Crowley (Norway), described a patient
clinically diagnosed with PCD and managed as having
Fig. 4 2nd BEAT-PCD Conference feedback survey respondents’ country of work
Fig. 5 2nd BEAT-PCD Conference feedback survey respondents’ area of expertise
Halbeisen et al. BMC Proceedings 2018, 12(Suppl 2):1 Page 13 of 17
PCD prior to the availability of PCD diagnostic
testing. 16 years later these investigations were
undertaken and found to be normal, highlighting the
importance of PCD diagnostic reference centres to be
available to confirm diagnoses.
 Woolf Walker (UK), described a teenager with
PCD and a severe respiratory phenotype (FEV1
15% predicted, oxygen dependent, on overnight
BiPAP support with end stage bronchiectasis) but,
despite this a good perceived quality of life. The
case highlighted the limited international
experience on lung transplant in PCD patients to
help inform decision making in such severe
patients.
 Nisreen Rumman (Palestine), described a
17-year-old diagnosed late with PCD despite
having typical clinical features since birth and a
deceased brother with lung disease. The patient
had a rapidly progressive course despite aggressive
management. The case highlighted the lack of
knowledge about PCD among general
practitioners that had led to the delay in
diagnosis and the difficulty of access to diagnosis
and some medications in resource limited
countries.
 Zorica Zivkovic (Serbia), described a 9-year-old
with sinopulmonary disease and ear infections
who was being treated as an atopic case; however
PCD investigations demonstrated immotile cilia.
The case highlighted the importance of keeping
high index of suspicion for PCD since the symptoms
are non-specific.
These cases and the discussions that followed,
highlighted both the difficulties in diagnosing and man-
aging these complex patients but also the disparities and
challenges in care provision across different countries.
Evaluation feedback from participants
An online survey was circulated to participants during the
Conference and Training School for feedback and to im-
prove subsequent BEAT-PCD Conferences. Sixty-two par-
ticipants from 21 countries (Fig. 4) responded, of which
47% ESRs. Participants from diverse multidisciplinary back-
grounds (Fig. 5) evaluated the selection of topics and the
time allocated to each of the conference sessions (Fig. 6).
Participants rated the overall conference 8.9 out of 10,
with 90% stating that their needs were fully addressed
independent of career stage. Plenary sessions, work-
shops, and opportunities for networking and discussing
new and ongoing projects were highlighted as the most
useful aspects of the conference. The majority of partici-
pants (93%) approved this year’s event format: a joint
Conference and Training School, with oral presentations
in the morning followed by interactive sessions (workshops,
difficult cases) in the afternoon.
Summary
The BEAT-PCD Conference and training school brought
together clinical PCD specialists (paediatricians and adult
pulmonologists, ENT, physiotherapists, specialist nurses)
and scientists from varied backgrounds (genetics, imaging,
cell biology, microbiology, bioinformatics). The multidis-
ciplinary conference provided an interactive platform for
research groups from 21 countries to exchange ideas
through a program of lectures, poster presentations,
breakout sessions and workshops. The next BEAT-PCD
conference and training school will be held in Lisbon,
Portugal in February 2018.
Additional file
Additional file 1: Aims, methods, outcomes and current status of
ongoing and new BEAT-PCD projects, presented at the 2nd BEAT-PCD
Conference & 3rd Training School. (DOCX 30 kb)
Fig. 6 Feedback survey respondents’ opinion on the structure of the 2nd BEAT-PCD Conference
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